PROCEPT (PRCT) EVP Nouri Alaleh Receives RSU and Option Awards

What Happened

• Nouri Alaleh, EVP, CLO and Corporate Secretary of PROCEPT BioRobotics (PRCT), received equity awards reported on a Form 4 dated 2026-08-14 for transactions on 2026-08-13. The filing shows:
  • 22,965 restricted stock units (RSUs) granted at $0.00 (no cash paid).
  • 31,773 derivative shares granted at $0.00 (described in the filing as a stock-option-type award per footnote).
• These are grants/awards (transaction code A), not open-market purchases or sales — typical employee equity compensation rather than a market trade.

Key Details

• Transaction date: August 13, 2026; Form 4 filed August 14, 2026 (appears timely).
• RSU grant: 22,965 RSUs; acquisition price $0.00.
  • Vesting (per footnote): 1/4 of the RSUs vest on August 13, 2027; thereafter the footnote states "one-sixteenth of the remaining RSUs vesting quarterly over 36 months," subject to continued service.
• Derivative/option-type award: 31,773 shares; acquisition price $0.00.
  • Vesting (per footnote): 1/48th of the shares vest monthly beginning August 13, 2026, over four years, subject to continued employment.
• Grant purpose: Each grant is described as intended to be 50% of the value of the reporting person's expected 2027 grant and was made in lieu of that portion of the expected 2027 grant.
• Post-transaction beneficial ownership: Not specified in the filing.
• Transaction code: A = Award/Grant. No sale or exercise was reported; no 10b5-1 or tax-withholding notes disclosed.

Context

• These awards are standard long-term compensation tied to continued service and future vesting; they do not represent an immediate sale or purchase in the open market. The RSUs convert to shares upon vesting; the derivative award is structured as an option-like grant with monthly vesting over four years.